Pages with the most revisions
Showing below up to 50 results in range #351 to #400.
View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)
- Collagen (1 revision)
- Protein synthesis initiation factor 5A (1 revision)
- Complement component C9 (1 revision)
- Dipeptidase 2 (1 revision)
- TG2 reactive residues (Actin) (1 revision)
- TG2 reactive residues (Melittin) (1 revision)
- Heparin cofactor 2 (1 revision)
- Ig alpha-1 chain C region (1 revision)
- 26S proteasome non-ATPase regulatory subunit 4 (1 revision)
- Insulin-like growth factor-binding protein 6 (1 revision)
- Keratin, type II cytoskeletal 1 (1 revision)
- Apolipoprotein C-III (1 revision)
- Monocyte differentiation antigen CD14 (1 revision)
- Uteroglobin (1 revision)
- Carboxypeptidase N subunit 2 (1 revision)
- Vitamin K-dependent protein S (1 revision)
- Complement factor B (1 revision)
- Sequestosome-1 (1 revision)
- TG2 reactive residues (Midkine) (1 revision)
- Tetranectin (1 revision)
- Ig alpha-2 chain C region (1 revision)
- Insulin-like growth factor-binding protein complex acid labile subunit (1 revision)
- Keratin intermediate filaments (1 revision)
- Apolipoprotein D (1 revision)
- C-type lectin domain family 11 member A (1 revision)
- Phosphatidylinositol-glycan-specific phospholipase D (1 revision)
- Cartilage oligomeric matrix protein (1 revision)
- Vitamin K-dependent protein Z (1 revision)
- Complement factor D (1 revision)
- Drebrin-like protein (1 revision)
- TG2 reactive residues (BHMT) (1 revision)
- Glucosidase 2 subunit beta (1 revision)
- TG2 reactive residues (Parkin) (1 revision)
- Hepatocyte growth factor-like protein (1 revision)
- Ig delta chain C region (1 revision)
- 72 kDa type IV collagenase (1 revision)
- Afamin (1 revision)
- Apolipoprotein E (1 revision)
- Beta-2-glycoprotein 1 (1 revision)
- Transcription factor AP-1 (1 revision)
- C-type mannose receptor 2 (1 revision)
- Vitronectin (1 revision)
- Platelet-derived growth factor receptor beta (1 revision)
- Proteoglycan 4 (1 revision)
- Complement factor H (1 revision)
- Small ubiquitin-related modifier 1 (1 revision)
- TG2 reactive residues (C1 inhibitor) (1 revision)
- TG2 reactive residues (Phospholipase A2) (1 revision)
- Hepatocyte growth factor activator (1 revision)
- Ig heavy chain V-III region BRO (1 revision)
